The proteasome inhibitor PS-341 in cancer therapy.
暂无分享,去创建一个
R. Herbst | B. Teicher | J. Adams | V. Palombella | J. Adams | G. Ara
[1] M. Grever,et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.
[2] S. Ōmura,et al. Total Synthesis of (+)-Lactacystin , 1996 .
[3] M. Ames,et al. Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo. , 1992, Invasion & metastasis.
[4] Tom Maniatis,et al. Regulation of Interferon-γ-Activated STAT1 by the Ubiquitin-Proteasome Pathway , 1996, Science.
[5] B. Teicher,et al. Transforming growth factor-β in in vivo resistance , 1996, Cancer Chemotherapy and Pharmacology.
[6] L. Ignarro,et al. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[7] R. Rousset,et al. Effects on NF-κB1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome , 1996, Nature.
[8] T. Maniatis,et al. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. , 1996, Science.
[9] D. Wolf,et al. Proteasome and cell cycle , 1993, FEBS letters.
[10] R F Standaert,et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.
[11] S. Schreiber,et al. A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Ōmura,et al. Degradation Process of Ligand-stimulated Platelet-derived Growth Factor β -Receptor Involves Ubiquitin-Proteasome Proteolytic Pathway * , 1995, The Journal of Biological Chemistry.
[13] A. Goldberg,et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.
[14] B. Teicher,et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. , 1990, Science.
[15] Wovkulich Peter Michael,et al. Total synthesis of 1233A , 1993 .
[16] D. Wolf,et al. Proteasomes: destruction as a programme. , 1996, Trends in biochemical sciences.
[17] S. Chatterjee,et al. Potent inhibitors of proteasome. , 1995, Journal of medicinal chemistry.
[18] Charles A. Kennedy,et al. Immunosuppresive boronic acid dipeptides: correlation between conformation and activity , 1993 .
[19] S. Ōmura,et al. Neuronal differentiation of Neuro 2a cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid. , 1995, Biochemical and biophysical research communications.
[20] S. Ōmura,et al. Lactacystin, an inhibitor of the proteasome, blocks the degradation of a mutant precursor of glycosylphosphatidylinositol-linked protein in a pre-Golgi compartment. , 1996, Biochemical and biophysical research communications.
[21] R. Stein,et al. Boronic ester and acid compounds, their synthesis and uses , 1995 .
[22] A B Shenvi,et al. alpha-Aminoboronic acid derivatives: effective inhibitors of aminopeptidases. , 1986, Biochemistry.
[23] S. Ōmura,et al. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. , 1995, Biochemical and biophysical research communications.
[24] Tom Maniatis,et al. The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.
[25] N. Soskel,et al. A new peptide boronic acid inhibitor of elastase-induced lung injury in hamsters. , 1986, The American review of respiratory disease.
[26] U. Lopes,et al. p53-dependent Induction of Apoptosis by Proteasome Inhibitors* , 1997, The Journal of Biological Chemistry.
[27] Charles A. Kennedy,et al. Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B-N Bond , 1994 .
[28] B. Teicher,et al. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.
[29] S. Ōmura,et al. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. , 1996, Cancer research.
[30] A. Goldberg,et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.
[31] B. Teicher,et al. Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents , 1994, International journal of cancer.
[32] J. Riordan,et al. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.
[33] B. Teicher,et al. Transforming growth factor-beta in in vivo resistance. , 1996, Cancer chemotherapy and pharmacology.
[34] P. Howley,et al. In vivo ubiquitination and proteasome-mediated degradation of p53(1). , 1996, Cancer research.
[35] J. Adams,et al. CHAPTER 28. NOVEL INHIBITORS OF THE PROTEASOME AND THEIR THERAPEUTIC USE IN INFLAMMATION , 1996 .
[36] A. Goldberg,et al. The molecular chaperone Ydj1 is required for the p34CDC28-dependent phosphorylation of the cyclin Cln3 that signals its degradation , 1996, Molecular and cellular biology.
[37] E. Sausville,et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.
[38] R. Knabb,et al. The selective inhibition of thrombin by peptides of boroarginine. , 1990, The Journal of biological chemistry.
[39] B. Teicher,et al. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. , 1987, Cancer research.
[40] M. Kirschner,et al. Ubiquitination of the G1 cyclin Cln2p by a Cdc34p‐dependent pathway. , 1995, The EMBO journal.
[41] Bruce Futcher,et al. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins , 1995, Nature.